Previous 10 | Next 10 |
Pfizer ( PFE +3.7% ) and development partner BioNTech SE ( BNTX +3.4% ) announce preliminary results from an ongoing Phase 1/2 clinical trial evaluating the safety, tolerability and immunogenicity of escalating doses of BNT162b1, the most advanced of their four investigational COVID-...
The data is quite technical and both Pfizer (NYSE: PFE ) and BioNTech (NASDAQ: BNTX ) are having conference calls later today to discuss. More news on: Pfizer Inc., BioNTech SE, Healthcare stocks news, Stocks on the move, Top Breaking stock news, Read more ...
This article was highlighted for PRO subscribers, Seeking Alpha's service for professional investors. Find out how you can get the best content on Seeking Alpha here . Executive Summary and Investment Conclusion We are short Moderna ( MRNA ), believing that the stock is trading in ...
Dividend increases are the name of the game. We invest in dividend growth stocks to earn a GROWING dividend income stream. That is why the two of us are constantly monitoring our portfolios , and potential investments, to see which companies will increase their dividend. Every month, we share...
In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD) is being evaluated in 45 subjects At day 28 (7 days after dose 2), all subjects...
In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD) is being evaluated in 45 subjects At day 28 (7 days after dose 2), all subjects ...
ROCKLAND, Mass. and NEW YORK , June 30, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada , and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Bi...
The FDA has released guidance on its standards for approving a COVID-19 vaccine, including a requirement that it must demonstrate that it is at least 50% more effective than placebo (a low bar compared to vaccines for other infectious diseases). More news on: AstraZeneca PLC, GlaxoSmithK...
More vaccine news to catch up on - previous updates and specific topic posts on this subject were on June 15 , on June 11 , on May 26, on May 18 (with two other posts), on May 14, on May 1, on April 23, and on April 15 (author's note: yikes). Keep in mind that some of those posts were update...
Although this article covers the results for the month of May, I did want to discuss a trade made during the month of June where we sold shares of Kimco ( KIM.PL ) Preferred Series L. As much as I would like to take credit for the timing of selling this holding I can honestly say it was lucky ...
News, Short Squeeze, Breakout and More Instantly...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
2024-05-17 21:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...